LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article ; Online: Assessment of the psychometric properties of the Spanish version of EORTC QLQ-MY20 and evaluation of health-related quality of Life outcomes in patients with relapsed and/or refractory multiple myeloma in the real-world setting in Spain: results from the CharisMMa study.

    Dachs, Laura Rosiñol / Gaisán, Carmen Montes / Bustamante, Gabriela / López, Sebastián Garzón / García, Esther González / Persona, Ernesto Pérez / González-Calle, Verónica / Auzmendi, Maialen Sirvent / Pérez, José Maria Arguiñano / González Montes, Yolanda / Ríos Tamayo, Rafael / de Miguel Llorente, Dunia / Bernal, Luis Palomera / Mayol, Antonia Sampol / Caro, Carmen Couto / Grande, Marta / Fernández-Nistal, Alonso / Naves, Andrea / Miguel, Enrique M Ocio San

    Leukemia & lymphoma

    2023  Volume 64, Issue 11, Page(s) 1847–1856

    Abstract: We evaluated the psychometric properties of the Spanish version of the European Organization for Research and Treatment of Multiple Myeloma (MM) specific quality-of-life (QoL) questionnaire module (QLQ-MY20) in relapsed/refractory MM (RRMM) patients. ... ...

    Abstract We evaluated the psychometric properties of the Spanish version of the European Organization for Research and Treatment of Multiple Myeloma (MM) specific quality-of-life (QoL) questionnaire module (QLQ-MY20) in relapsed/refractory MM (RRMM) patients. This was an observational, cross-sectional, multicenter study using EORTC QLQ-C30 and QLQ-MY20 in RRMM patients (ClinicalTrials.gov ID NCT03188536). We assessed the non-response rate, ceiling/floor effects, internal consistency, test-retest reliability, and validity. The study included 276 patients (53.3% males, mean [SD] age of 67.4 [10.5] years). The EORTC QLQ-MY20 showed a low non-response rate, very low ceiling and floor effects, and good internal consistency. The test-retest reliability assessment revealed good temporary stability, the construct validity analysis stated four main factors similar to the ones of the original version, and the criterion validity assessment showed no differences between groups. In conclusion, the Spanish version of EORTC QLQ-MY20 is a reliable and valid tool for assessing QoL in RRMM patients.
    MeSH term(s) Female ; Humans ; Male ; Cross-Sectional Studies ; Multiple Myeloma/diagnosis ; Multiple Myeloma/epidemiology ; Multiple Myeloma/therapy ; Psychometrics ; Quality of Life ; Reproducibility of Results ; Spain/epidemiology ; Middle Aged ; Aged
    Language English
    Publishing date 2023-08-04
    Publishing country United States
    Document type Observational Study ; Multicenter Study ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1042374-6
    ISSN 1029-2403 ; 1042-8194
    ISSN (online) 1029-2403
    ISSN 1042-8194
    DOI 10.1080/10428194.2023.2240922
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2997: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Clinical outcomes after CPX-351 in patients with high-risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry.

    Bernal, Teresa / Moreno, Ainhoa Fernández / de LaIglesia, Almudena / Benavente, Celina / García-Noblejas, Ana / Belmonte, Daniel García / Riaza, Rosalía / Salamero, Olga / Foncillas, Maria Angeles / Roldán, Alicia / Concepción, Víctor Noriega / González, Laura Llorente / Bergua Burgués, Juan Miguel / Lorente de Uña, Soraya / Rodríguez-Macías, Gabriela / de la Fuente Burguera, Adolfo / García Pérez, Maria José / López-Lorenzo, Jose Luis / Martínez, Pilar /
    Aláez, Concepción / Callejas, Marta / Martínez-Chamorro, Carmen / Roca, José Rifón / Barciela, Lourdes Amador / Mena Durán, Armando V / Gómez Correcha, Karoll / Lavilla Rubira, Esperanza / Amigo, María Luz / Vall-Llovera, Ferran / Garrido, Ana / García-Fortes, María / de Miguel Llorente, Dunia / Leonardo, Anastasia Aules / Cervero, Carlos / Jordá, Rosa Coll / Pérez-Encinas, Manuel M / Zarzuela, Marta Polo / Figuera, Angela / Rad, Guillermo / Martínez-Cuadrón, David / Montesinos, Pau

    Cancer medicine

    2023  Volume 12, Issue 14, Page(s) 14892–14901

    Abstract: Background: CPX-351 is approved for the treatment of therapy related acute myeloid leukemia (t-AML) and AML with myelodysplastic related changes (MRC-AML). The benefits of this treatment over standard chemotherapy has not been addressed in well matched ... ...

    Abstract Background: CPX-351 is approved for the treatment of therapy related acute myeloid leukemia (t-AML) and AML with myelodysplastic related changes (MRC-AML). The benefits of this treatment over standard chemotherapy has not been addressed in well matched cohorts of real-life patients.
    Methods: Retrospective analysis of AML patients treated with CPX-351 as per routine practice. A propensity score matching (PSM) was used to compare their main outcomes with those observed in a matched cohort among 765 historical patients receiving intensive chemotherapy (IC), all of them reported to the PETHEMA epidemiologic registry.
    Results: Median age of 79 patients treated with CPX-351 was 67 years old (interquartile range 62-71), 53 were MRC-AML. The complete remission (CR) rate or CR without recovery (CRi) after 1 or 2 cycles of CPX-351 was 52%, 60-days mortality 18%, measurable residual disease <0.1% in 54% (12 out of 22) of them. Stem cell transplant (SCT) was performed in 27 patients (34%), median OS was 10.3 months, and 3-year relapse incidence was 50%. Using PSM, we obtained two comparable cohorts treated with CPX-351 (n = 52) or IC (n = 99), without significant differences in CR/CRi (60% vs. 54%) and median OS (10.3 months vs. 9.1 months), although more patients were bridged to SCT in the CPX-351 group (35% vs. 12%). The results were confirmed when only 3 + 7 patients were included in the historical cohort. In multivariable analyses, SCT was associated with better OS (HR 0.33 95% CI: 0.18-0.59), p < 0.001.
    Conclusion: Larger post-authorization studies may provide evidence of the clinical benefits of CPX-351 for AML in the real-life setting.
    MeSH term(s) Humans ; Aged ; Retrospective Studies ; Cytarabine/therapeutic use ; Remission Induction ; Leukemia, Myeloid, Acute
    Chemical Substances CPX-351 ; Cytarabine (04079A1RDZ)
    Language English
    Publishing date 2023-05-22
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2659751-2
    ISSN 2045-7634 ; 2045-7634
    ISSN (online) 2045-7634
    ISSN 2045-7634
    DOI 10.1002/cam4.6120
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group.

    Palanques-Pastor, Tomás / Megías-Vericat, Juan Eduardo / Martínez, Pilar / López Lorenzo, José Luis / Cornago Navascués, Javier / Rodriguez Macias, Gabriela / Cano, Isabel / Arnan Sangerman, Montserrat / Vidriales Vicente, María Belén / Algarra Algarra, Jesús Lorenzo / Foncillas, María Ángeles / Herrera, Pilar / Botella Prieto, Carmen / Vives, Susana / Figuera Álvarez, Ángela / Cuevas Palomares, Laida / Sobas, Marta / Contento Gonzalo, Alejandro / Cuello García, Rebeca /
    Amutio Diez, María Elena / De Miguel Llorente, Dunia / Navas Elorza, Begoña / Bergua Burgues, Juan Miguel / Bernal Del Castillo, Teresa / Mateos Rodríguez, María Carmen / de Cabo López, Erik / Franco Villegas, Ana Carolina / García Boyero, Raimundo / Escolano Escobar, Cristian / Seri Merino, Cristina / Cervero, Carlos / Roldán Pérez, Alicia / Hermosín Ramos, Lourdes / Cervera Calvo, Marta / Olave, María Telesa / Villafuerte Gutiérrez, Paola / de Laiglesiai, Almudena / Serrano, Josefina / Najera Irazu, María Josefa / Piñana, José Luis / Sanz, Miguel Ángel / Martínez-López, Joaquín / Montesinos, Pau

    Leukemia & lymphoma

    2021  Volume 62, Issue 12, Page(s) 2928–2938

    Abstract: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection produces higher morbidity and mortality in hematological malignancies, but evidence in acute myeloid leukemia (AML) is scarce. A multicenter observational study was conducted to ... ...

    Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection produces higher morbidity and mortality in hematological malignancies, but evidence in acute myeloid leukemia (AML) is scarce. A multicenter observational study was conducted to determine the clinical outcomes and assess the impact of therapeutic approaches in adult AML patients with SARS-CoV-2 infection in the first wave (March-May 2020). Overall, 108 patients were included: 51.9% with active leukemia and 70.4% under therapeutic schedules for AML. Signs and symptoms of SARS-CoV-2 were present in 96.3% of patients and 82.4% received specific treatment for SARS-CoV-2. The mortality rate was 43.5% and was correlated with age, gender, active leukemia, dyspnea, severe SARS-CoV-2, intensive care measures, neutrophil count, and D-dimer levels. A protective effect was found with azithromycin, lopinavir/ritonavir, and normal liver enzyme levels. During the SARS-CoV-2 first wave, our findings suggested an increased mortality in AML in a short period. SARS-CoV-2 management could be guided by risk factors in AML patients.
    MeSH term(s) Adult ; COVID-19 ; Humans ; Leukemia, Myeloid, Acute/epidemiology ; Leukemia, Myeloid, Acute/therapy ; Lopinavir ; Risk Factors ; SARS-CoV-2
    Chemical Substances Lopinavir (2494G1JF75)
    Language English
    Publishing date 2021-07-22
    Publishing country United States
    Document type Journal Article ; Multicenter Study ; Observational Study
    ZDB-ID 1042374-6
    ISSN 1029-2403 ; 1042-8194
    ISSN (online) 1029-2403
    ISSN 1042-8194
    DOI 10.1080/10428194.2021.1948031
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2997: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top